加载中
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.
常规交易时段
US$85.385
+US$4.295 · +5.30%
盘中时间采用ET。市场数据可能有所延迟。
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.
日内区间
当前US$85.385
52周区间
当前US$85.385
盘中时间采用ET。市场数据可能有所延迟。
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.
日内区间
当前US$85.385
52周区间
当前US$85.385
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2022年2月23日 | 5:1 | — | — |
已生效 2022年2月23日
5:1
报告持有此股票敞口的交易所交易基金。
State Street SPDR S&P Biotech ETFXBI1.09亿1.09%100.51亿 USD0.35%US$149.95+2.16%
iShares Russell 2000 ETFIWM8581.23万0.11%755.95亿 USD0.19%US$273.03+0.61%
Vanguard Morningstar Total Stock Market ETFVTI4818.83万0.00%2.3万亿 USD0.03%US$376.97+0.02%
iShares Biotechnology ETFIBB3608.78万0.34%104.97亿 USD0.44%US$208.37+2.52%
iShares Russell 2000 Growth ETFIWO2959.24万0.22%133.81亿 USD0.24%US$344.14+0.38%
Vanguard Extended Market ETFVXF1784.69万0.02%954亿 USD0.05%US$228.81+0.46%
Schwab U.S. Small-Cap ETFSCHA1690.15万0.08%216.55亿 USD0.03%US$32.225+0.73%
Fidelity Enhanced Small Cap ETFFESM1258.27万0.19%64.1亿 USD0.28%US$44.63+0.50%State Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Morningstar Total Stock Market ETFVTIiShares Biotechnology ETFIBBiShares Russell 2000 Growth ETFIWOVanguard Extended Market ETFVXFSchwab U.S. Small-Cap ETFSCHAFidelity Enhanced Small Cap ETFFESMAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
